Aplastic Anemia Market Expected to Experience Accelerated Growth and Market Evolution by 2036 - DelveInsight | Pfizer, Regeneron Pharma, Gamida-Cell, Kyowa Kirin, Novartis, Jiangsu HengRui

The Key Aplastic Anemia Companies in the market include - Teva Pharmaceuticals, Pfizer, Regeneron Pharmaceuticals, Gamida-Cell, Kyowa Kirin, Novartis, Jiangsu HengRui Medicine Co., Ltd., Janssen Scientific Affairs, LLC, and others.

DelveInsight's "Aplastic Anemia Market Insights, Epidemiology, and Market Forecast-2036 report offers an in-depth understanding of the Aplastic Anemia, historical and forecasted epidemiology as well as the Aplastic Anemia market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Get a Free sample for the Aplastic Anemia Market Report

https://www.delveinsight.com/sample-request/aplastic-anemia-market [https://www.delveinsight.com/sample-request/aplastic-anemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Aplastic Anemia Market Report:

*
The Acromegaly market size was valued at approximately USD 1.3 billion in 2025 and is expected to experience steady growth during the forecast period from 2026 to 2036, registering a CAGR of around 1.5%.

*
Regeneron announced in 2025 that they have discontinued the study of REGN7257 in Aplastic anemia.

*
In February 2026, Ayrmid announced presentation of additional positive results for OMISIRGE in treating SAA at TANDEM 2026.

*
In April 2025, Cellenkos announced that the US FDA had granted ODD to its novel cell therapy product, CK0801. Cellenkos was planning for a registration trial of CK0801 in H2 2025.

*
In December 2025, Ayrmid Ltd. ("Ayrmid" or the "Company"), the parent organization of Gamida Cell Inc., a pioneer in cell therapy innovation, has announced that the U.S. Food and Drug Administration ("FDA") has approved Omisirge (Omidubicel-onlv) for treating Severe Aplastic Anemia (SAA).

*
In September 2025, Omidubicel is a nicotinamide-modified allogeneic hematopoietic progenitor cell therapy sourced from cord blood. Marketed as Omisirge Registered , it is approved for adults and pediatric patients aged 12 and older with hematologic malignancies who are scheduled for umbilical cord blood transplantation following myeloablative conditioning, aiming to shorten neutrophil recovery time and lower the risk of infection.

*
According to DelveInsight's analysis, the Aplastic anemia market across the 7MM reached approximately USD 300 million in 2025, with the US holding the largest share.

*
The overall market of Aplastic anemia in the 7MM is expected to cross USD 300 million by 2036.

*
The aplastic anemia market is projected to decline from 2026 onward, driven by the anticipated entry of generic versions of PROMACTA.

*
Treatment for SAA in the elderly is uncertain, considering both illness characteristics and the patient's health to minimize treatment-related risks. Hematopoietic cell transplantation (HCT) is often a second-line choice for elderly SAA patients.

*
As per DelveInsight estimates, the total incident population of aplastic anemia in the 7MM was around 2,600 cases in 2025. These cases are projected to increase during the forecast period.

*
Japan accounted for the highest Incident cases of aplastic anemia in the 7MM in 2025, with approximately 850 cases.

*
In the United States, it is observed that aplastic anemia occurs primarily in the age group of 60 years and above, accounting for ~56% of all cases, in 2025.

*
Among EU4 and the UK, Germany accounted for the highest number of aplastic anemia cases, followed by France, whereas Spain accounted for the lowest number of cases in 2025.

*
Among the severity-specific cases, SAA was more common in the United States, with ~430 cases in 2025.

*
Key Aplastic Anemia Companies: Teva Pharmaceuticals, Pfizer, Regeneron Pharmaceuticals, Gamida-Cell, Kyowa Kirin, Novartis, Jiangsu HengRui Medicine Co., Ltd., Janssen Scientific Affairs, LLC, and others

*
Key Aplastic Anemia Therapies: ALVAIZ (eltrombopag choline), PF-06462700, REGN7257, Omidubicel, Romiplostim, Eltrombopag, AMG531, Eltrombopag, Hetrombopag Olamine, Ibrutinib, and others

*
The Aplastic Anemia epidemiology based on gender analyzed that the male-to-female ratio is approximately 1:1

*
The Aplastic Anemia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Aplastic Anemia pipeline products will significantly revolutionize the Aplastic Anemia market dynamics.

Aplastic Anemia Overview

According to the National Institutes of Health, pancytopenia and decreased or nonexistent hematopoietic precursors in the bone marrow are symptoms of aplastic anaemia, which is a state of chronic primary hematopoietic failure brought on by damage.

To Know in detail about the Aplastic Anemia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Aplastic Anemia Market Forecast [https://www.delveinsight.com/report-store/aplastic-anemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Aplastic Anemia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Aplastic Anemia Epidemiology Segmentation:

The Aplastic Anemia market report proffers epidemiological analysis for the study period 2022-2036 in the 7MM segmented into:

*
Total Incident Cases of Aplastic Anemia

*
Severity-specific Cases of Aplastic Anemia

*
Age-specific Cases of Aplastic Anemia

Download the report to understand which factors are driving Aplastic Anemia epidemiology trends @ Aplastic Anemia Epidemiology Forecast [https://www.delveinsight.com/report-store/aplastic-anemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Aplastic Anemia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Aplastic Anemia market or expected to get launched during the study period. The analysis covers Aplastic Anemia market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Aplastic Anemia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Aplastic Anemia Therapies and Key Companies

*
OMISIRGE (omidubicel-onlv): Ayrmid (Gamida Cell)

*
ALVAIZ (eltrombopag choline): Teva Pharmaceuticals

*
ROMIPLATE (romiplostim): Kyowa Kirin

*
CK0801: Cellenkos

*
ALVAIZ (eltrombopag choline): Teva Pharmaceuticals

*
REGN7257: Regeneron Pharmaceuticals

*
PF-06462700: Pfizer

*
Omidubicel: Gamida-Cell

*
Romiplostim: Kyowa Kirin

*
Eltrombopag: Novartis

*
AMG531: Kyowa Kirin

*
Eltrombopag: Novartis

*
Hetrombopag Olamine: Jiangsu HengRui Medicine Co., Ltd.

*
Ibrutinib: Janssen Scientific Affairs, LLC

Discover more about therapies set to grab major Aplastic Anemia market share @ Aplastic Anemia Treatment Market [https://www.delveinsight.com/report-store/aplastic-anemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Aplastic Anemia Market Drivers

*
Increasing awareness and improved diagnosis: Greater awareness among healthcare professionals and advancements in diagnostic techniques are leading to earlier and more accurate detection of aplastic anemia.

*
Advancements in treatment options: The development of immunosuppressive therapies, hematopoietic stem cell transplantation, and novel targeted therapies is improving patient outcomes and driving market growth.

*
Growing investment in rare disease research: Pharmaceutical companies and research organizations are increasing investments in rare hematologic disorders, supporting new drug development.

*
Rising healthcare expenditure: Improved access to advanced healthcare facilities and treatment options is contributing to increased adoption of therapies.

Aplastic Anemia Market Barriers

*
High cost of treatment: Advanced therapies such as stem cell transplantation and long-term immunosuppressive treatments can be expensive, limiting accessibility.

*
Limited donor availability for transplantation: Successful hematopoietic stem cell transplantation often depends on compatible donors, which can restrict treatment options.

*
Adverse effects associated with therapies: Immunosuppressive treatments and transplantation procedures may cause significant side effects and complications.

*
Limited patient population: As a rare disease, the smaller patient pool may restrict market expansion and reduce commercial incentives for drug development.

*
Regulatory and clinical trial challenges: Stringent regulatory requirements and difficulties in recruiting patients for trials can delay the approval of new therapies.

Scope of the Aplastic Anemia Market Report

*
Study Period: 2022-2036

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Aplastic Anemia Companies: Teva Pharmaceuticals, Pfizer, Regeneron Pharmaceuticals, Gamida-Cell, Kyowa Kirin, Novartis, Jiangsu HengRui Medicine Co., Ltd., Janssen Scientific Affairs, LLC, and others

*
Key Aplastic Anemia Therapies: ALVAIZ (eltrombopag choline), PF-06462700, REGN7257, Omidubicel, Romiplostim, Eltrombopag, AMG531, Eltrombopag, Hetrombopag Olamine, Ibrutinib, and others

*
Aplastic Anemia Therapeutic Assessment: Aplastic Anemia current marketed and Aplastic Anemia emerging therapies

*
Aplastic Anemia Market Dynamics: Aplastic Anemia market drivers and Aplastic Anemia market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Aplastic Anemia Unmet Needs, KOL's views, Analyst's views, Aplastic Anemia Market Access and Reimbursement

To know more about Aplastic Anemia companies working in the treatment market, visit @ Aplastic Anemia Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/report-store/aplastic-anemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Aplastic Anemia Market Report Introduction

2. Executive Summary for Aplastic Anemia

3. SWOT analysis of Aplastic Anemia

4. Aplastic Anemia Patient Share (%) Overview at a Glance

5. Aplastic Anemia Market Overview at a Glance

6. Aplastic Anemia Disease Background and Overview

7. Aplastic Anemia Epidemiology and Patient Population

8. Country-Specific Patient Population of Aplastic Anemia

9. Aplastic Anemia Current Treatment and Medical Practices

10. Aplastic Anemia Unmet Needs

11. Aplastic Anemia Emerging Therapies

12. Aplastic Anemia Market Outlook

13. Country-Wise Aplastic Anemia Market Analysis (2022-2036)

14. Aplastic Anemia Market Access and Reimbursement of Therapies

15. Aplastic Anemia Market Drivers

16. Aplastic Anemia Market Barriers

17. Aplastic Anemia Appendix

18. Aplastic Anemia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=aplastic-anemia-market-expected-to-experience-accelerated-growth-and-market-evolution-by-2036-delveinsight-pfizer-regeneron-pharma-gamidacell-kyowa-kirin-novartis-jiangsu-hengrui]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.